Overview
Vitalhub Q2 total revenue up 47% YoY to CAD 23.9 mln, beating estimates, per LSEG data
Adjusted EBITDA rises 50% YoY to CAD 6.3 mln
Annual recurring revenue grows 55% YoY to CAD 79.6 mln
Outlook
Company aims to continue international expansion with current cash and ARR
Result Drivers
ORGANIC GROWTH - Organic ARR growth contributed C$1.9 mln in Q2, reflecting ongoing expansion efforts
FOREIGN EXCHANGE - ARR benefited from C$170,566 gain due to favorable foreign exchange rate fluctuations
Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Beat
C$23.90 mln
C$22 mln (9 Analysts)
Q2 Adjusted EBITDA
C$6.30 mln
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"
Wall Street's median 12-month price target for Vitalhub Corp is C$15.00, about 9.4% above its August 7 closing price of C$13.59
The stock recently traded at 58 times the next 12-month earnings vs. a P/E of 46 three months ago
Press Release: ID:nGNX922bmp
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
